Guggenheim raised the firm’s price target on CymaBay (CBAY) to $28 from $24 and keeps a Buy rating on the shares. FDA acceptance of the seladelpar NDA “could be the impetus for potential M&A activity,” says the firm, which has evaluated potential strategic fits based on the acquirers rare disease and metabolic disease exposure, commercial need, and acquisitiveness. In that context, the firm believes Gilead (GILD), Takeda (TAK) Novo Nordisk (NVO) and GSK (GSK) are “the best fits.” The firm thinks an acquisition price of $37-$55 per share “could be reasonable” based on current Street and Guggenheim estimates, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CBAY:
- CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CymaBay: Analysis of Phase 3 ENHANCE study published in Hepatology
- The biotech stocks to own in 2024, according to Piper Sandler
- CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
- CymaBay Chief Commercial Officer to exit company